Clinical Evaluation Report Requirements for Class C and D Devices in Iran

1. Key takeaways

Iran requires a clinical evaluation report for Class C and Class D devices; clinical data generated outside Iran can in principle be accepted, but the review will probe population applicability. Population applicability is the hinge on which the acceptability of foreign data turns. The judgement of GRZAN is that foreign data are usable, but they must be accompanied by a population applicability analysis; data covering Middle Eastern or West Asian populations form a clear plus. Where such data exist, they belong in the analysis, stated plainly. For novel technologies, or technology routes that have not been used in Iran, supplementary local clinical data may be requested. The analysis is not decorative; it is what makes foreign data usable at all. Anticipating the request is far cheaper than answering it.

• A clinical evaluation report is required for Class C and Class D devices.
• Foreign clinical data are acceptable in principle, provided they are accompanied by a population applicability analysis. The analysis is what the reviewer reads first when the data are foreign.
• Data covering Middle Eastern or West Asian populations strengthen the submission visibly.
• Novel technologies or technologies unused in Iran may trigger requests for supplementary local clinical data. All three signals are visible before submission, so the self-assessment belongs at project initiation.

2. Legal basis

The legal and normative references supporting this module are the following.

1. Clinical evidence requirements for the high-risk classes: Class C and Class D devices must provide stricter clinical evaluation or trial evidence — based on publicly available industry materials; no official Iranian document number has been released through public channels, so this is a practical estimate.
2. The GHTF clinical evidence document system: the internationally customary way of organising clinical evaluation, generally accepted in Iran — this is a practical estimate.
3. Law on the Administration of Medical, Pharmaceutical and Food-Beverage Affairs, FAOLEX LEX-FAOC227692, 1955-06-20, Article 3.

3. Expert insights

Insight 1: the population applicability analysis is the “border-crossing document” for foreign data. Clinical data produced on East Asian populations and data produced on European or American populations do not extrapolate to the Iranian population with the same persuasiveness, and the reviewer’s questions will follow exactly this line. The difference between a submission that anticipates the question and one that answers it under pressure is structural: an analysis submitted proactively, with the data sources, the population characteristics and the extrapolation reasoning laid out, frames the discussion on the applicant’s terms. Population differences that bear on the claims should be reflected in the claims themselves. Waiting for the deficiency request hands that framing to the reviewer, along with the impression that the analysis was performed only because it was demanded. The comparison should be honest; a flattering comparison collapses under the first follow-up question. Extrapolation that is argued is accepted far more readily than extrapolation that is assumed.

Insight 2: the timeliness of the literature review is checked. Relevant research from the last 5 years is usually treated as the effective search window. The search must therefore be recent enough to cover the window, and — just as important — reproducible: the search strategy, the list of databases, the time window and the screening process must be recorded in full, so the reviewer can verify how the evidence base was assembled. A literature review that presents conclusions without its retrieval trail cannot be checked, and an unverifiable review is treated as no review at all. The archive of the search process is not bureaucracy; it is what makes the review’s conclusions evidence. The window is measured at the time of submission, so the review should be refreshed close to the filing date, and the search strings recorded exactly as executed. A complete trail also protects the applicant if the review is later re-examined.

Insight 3: the trigger conditions for local clinical data can be anticipated. Novel technology, no similar product marketed in Iran, or too large a population gap in the foreign data are the three main trigger conditions for a request for local clinical data. None of the three is hidden; all of them can be assessed from information available at project initiation. A company that runs this self-assessment early knows whether its dossier should include a contingency plan for local clinical work, and can begin contacting Iranian clinical institutions in parallel with the submission rather than after a deficiency request. Anticipation turns a potential months-long interruption into a planned activity. None of the three conditions is hidden, and none of them improves with delay; the assessment should be repeated if the technology or the market position changes.

4. Practical recommendations

• Make the population applicability analysis a standalone chapter: describe the data sources, the population characteristics and the reasonableness of the extrapolation, placed where the reviewer meets it before the data themselves.
• Record the search strategy in full: the databases, the search strings, the time window and the screening process all archived, complete enough for a third party to reproduce the review.
• Pre-plan a local clinical protocol: when one of the three trigger conditions applies, contact Iranian clinical institutions early — before the submission, not after a deficiency request.
• Submit the benefit-risk analysis together with the evaluation: the conclusions of the clinical evaluation must land on a benefit-risk determination, kept consistent with the risk management conclusions.

5. Verification checklist

• □ The clinical evaluation report has been submitted, including the population applicability analysis
• □ The literature search strategy, databases, time window and screening process have been archived in full
• □ A self-assessment has been made of whether the three local clinical data trigger situations apply
• □ The benefit-risk analysis has been submitted together with the clinical evaluation
• □ Initial contact has been made with local clinical institutions (where required)

Regulatory information verified as of October 29, 2026

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iranian market. Our team prepares IFDA-compliant dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com